Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News TG Therapeutics Inc TGTX

Healthcare Biotechnology
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TGTX)

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

GlobeNewswire 5 days ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

GlobeNewswire March 19, 2026

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

GlobeNewswire March 9, 2026

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire March 6, 2026

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

GlobeNewswire February 26, 2026

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

GlobeNewswire February 23, 2026

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

GlobeNewswire February 17, 2026

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

GlobeNewswire February 8, 2026

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire February 6, 2026
View More News ››

Opinion & Analysis (NDAQ:TGTX)

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016
View More Opinion ››

Bullboard Posts (NDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX): Briumvi Drives Impressi

http://beyondspx.com/2024/08/02/tg-therapeutics-inc-nasdaqtgtx-briumvi-drives-impressive-q1-2024-results-raising-full-year-guidance/
MikeTester - August 3, 2024

therapeutic gift

Check out this amazing investment opportunity: I just bought shares of XYZ company at $10, and sold a call option with a strike price of ...
stockpsycho - May 10, 2023

Now approved!

That's my Christmas gift to myself. 
hoffbag - December 28, 2022

What a Christmas gift

Got to love gifts like this Bot stock $8.25 Sold Jan 2023 $10 Call for $2 If FDA comes thru and SP is above $10 in less than 30 days...
Ogopogo007 - December 23, 2022

Any hope of recovery?

The stock is heading sout with 'strong buy' recommendation.  Where is the disconnect?
yellowtab - November 3, 2017
View more Bullboard ››

Atlas Salt Inc.

Atlas Salt Inc.

Atlas Salt Inc. engages in the evaluation, exploration and development of mineral properties in Newfoundland and Labrador ...
View More »

Podcasts